Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Añadir filtros








Intervalo de año
1.
Asia Oceania Journal of Nuclear Medicine and Biology. 2013; 1 (1): 20-26
en Inglés | IMEMR | ID: emr-130672

RESUMEN

The current study aimed to determine the efficacy of radioiodine-131 [131I] ablation therapy with thyroid hormone replacement one day before [131]I administration in patients with well-differentiated thyroid cancer [DTC]. This retrospective study included 29 patients who underwent [131]I therapies twice for DTC during 6-12 months. Since all the patients obviously had residual lesions by their serum thymoglobulin levels or their scintigrams at the first therapies, they underwent the second [131]I therapies without diagnostic scintigraphy after the first therapies. After confirming the sufficient elevation of TSH concentration, thyroid hormone replacement was resumed one day before [131]I administration [3.7-7.4GBq]. The ablation rate of thyroid remnant at the first [131]I therapy was evaluated by comparing [131]I post-therapeutic images of the two treatments. Three patients were administrated thyroid hormone after [131]I therapy because of insufficient TSH concentration under thyroid hormone withdrawal. In the remaining 26 patients, 41 thyroid remnant accumulations were detected in all 26 patients at the first [131]I therapy. Based on the second [131]I post-therapeutic images, successful ablation was confirmed in 24 of 26 patients [92.3%] and 38 of 41 sites [92.7%], which was comparable with historically reported ablation rates. Thyroid hormone replacement one day before [131]I therapy could provide a sufficiently high ablation rate in patients with DTC


Asunto(s)
Humanos , Masculino , Femenino , Terapia de Reemplazo de Hormonas , Hormonas Tiroideas , Radioisótopos de Yodo , Estudios Retrospectivos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA